DK3397622T3 - Co-administration af alpha-aminoester af hydroxypropylthiazolidincarboxamid-derivat og et tokolytisk middel - Google Patents

Co-administration af alpha-aminoester af hydroxypropylthiazolidincarboxamid-derivat og et tokolytisk middel Download PDF

Info

Publication number: DK3397622T3
Authority: DK; Denmark
Prior art keywords: tokolytisk; hydroxypropylthiazolidincarboxamid; middel; derivat; aminoester
Prior art date: 2016-01-04

Application number

DK17700391.0T

Other languages

English (en)

Inventor

Page Patrick Naxos

Matthias Schwarz

Catherine Jorand-Lebrun

Vincent Pomel

Ernest Loumaye

Oliver Pohl

Jean-Pierre Gotteland

Anna Quattropani

Original Assignee

ObsEva SA

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-01-04

Filing date

2017-01-04

Publication date

2022-06-07

2016-01-04 Priority claimed from US14/987,586 external-priority patent/US9447055B1/en

2017-01-04 Application filed by ObsEva SA filed Critical ObsEva SA

2022-06-07 Application granted granted Critical

2022-06-07 Publication of DK3397622T3 publication Critical patent/DK3397622T3/da

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D277/06—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Reproductive Health (AREA)
Endocrinology (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pregnancy & Childbirth (AREA)
Gynecology & Obstetrics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Thiazole And Isothizaole Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Cephalosporin Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pain & Pain Management (AREA)
Pyrrole Compounds (AREA)
Rheumatology (AREA)
Peptides Or Proteins (AREA)
Investigating Or Analysing Biological Materials (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Medicinal Preparation (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Emergency Medicine (AREA)

DK17700391.0T 2016-01-04 2017-01-04 Co-administration af alpha-aminoester af hydroxypropylthiazolidincarboxamid-derivat og et tokolytisk middel DK3397622T3 (en)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US201662274674P	2016-01-04	2016-01-04
US14/987,586 US9447055B1 (en)	2016-01-04	2016-01-04	α-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof
US201662395664P	2016-09-16	2016-09-16
US201662407918P	2016-10-13	2016-10-13
PCT/EP2017/050099 WO2017118639A1 (en)	2016-01-04	2017-01-04	Alpha-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof

Publications (1)

Publication Number	Publication Date
DK3397622T3 true DK3397622T3 (en)	2022-06-07

Family

ID=57799697

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK17700391.0T DK3397622T3 (en)	2016-01-04	2017-01-04	Co-administration af alpha-aminoester af hydroxypropylthiazolidincarboxamid-derivat og et tokolytisk middel
DK17700392.8T DK3400217T3 (da)	2016-01-04	2017-01-04	L-valinat af hydroxypropylthiazolidincarboxamid-derivat, dets salt og krystalform deraf

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK17700392.8T DK3400217T3 (da)	2016-01-04	2017-01-04	L-valinat af hydroxypropylthiazolidincarboxamid-derivat, dets salt og krystalform deraf

Country Status (25)

Country	Link
EP (4)	EP4140988A1 (da)
JP (6)	JP6933322B2 (da)
KR (3)	KR20180100120A (da)
CN (1)	CN108779087A (da)
AU (5)	AU2017205254B2 (da)
CA (2)	CA3009576A1 (da)
CY (2)	CY1125223T1 (da)
DK (2)	DK3397622T3 (da)
EA (1)	EA036990B1 (da)
ES (2)	ES2916835T3 (da)
HR (2)	HRP20220673T1 (da)
HU (2)	HUE058872T2 (da)
IL (5)	IL318222A (da)
LT (2)	LT3400217T (da)
MA (2)	MA43549A (da)
MX (3)	MX389261B (da)
PL (2)	PL3397622T3 (da)
PT (2)	PT3397622T (da)
RS (2)	RS63286B1 (da)
SG (4)	SG10202009723PA (da)
SI (2)	SI3400217T1 (da)
SM (2)	SMT202200248T1 (da)
UA (2)	UA125118C2 (da)
WO (2)	WO2017118639A1 (da)
ZA (1)	ZA201903769B (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA3009576A1 (en) *	2016-01-04	2017-07-13	Merck Serono S.A.	L-valinate of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof
RU2711615C1 (ru) *	2019-09-12	2020-01-17	Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт акушерства, гинекологии и репродуктологии имени Д.О. Отта"	Способ лечения эндометриоза на основании экспериментальной модели у крыс
CN114728013A (zh) *	2019-09-23	2022-07-08	斯坦福大学托管董事会	延长妊娠以及月经或妊娠的并发症的治疗方法
US12426782B2 (en)	2020-11-06	2025-09-30	The Board Of Trustees Of The Leland Stanford Junior University	Systems and temporal alignment methods for evaluation of gestational age and time to delivery
US20240024295A1 (en) *	2020-12-11	2024-01-25	Elise A. Olsen	Compositions and methods for inhibiting hair growth

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3835175A (en)	1971-03-15	1974-09-10	Research Corp	9-fluorenylmethanol haloformates, carbonates and thiocarbonates
US3839396A (en)	1971-07-15	1974-10-01	Shionogi & Co	9-lower alkyl-9-fluorenyl carbonates
US4108846A (en)	1977-02-01	1978-08-22	Hoffmann-La Roche Inc.	Solid phase synthesis with base N alpha-protecting group cleavage
SE430885B (sv)	1980-03-24	1983-12-19	Ferring Ab	Oxytocin-derivat
US4508657A (en)	1982-01-19	1985-04-02	Research Corporation	Peptide synthesis and amino acid blocking agents
US4581167A (en)	1982-01-19	1986-04-08	Research Corporation	Peptide synthesis and amino acid blocking agents
DE10075020I2 (de)	1982-12-21	2003-01-09	Ferring Ab	Vasotocinderivate
US4460501A (en)	1983-08-30	1984-07-17	Research Corporation	Process for the synthesis of peptides utilizing thioxanthylmethyloxycarbonyl dioxides
US5370135A (en) *	1993-10-13	1994-12-06	Biex, Inc.	Use of estriol measurement to monitor tocolytic therapy
DE4434488A1 (de) *	1994-09-14	1996-03-21	Schering Ag	Steroidester und -amide, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
SE9604341D0 (sv)	1996-11-26	1996-11-26	Ferring Bv	Hepta-peptide oxytocin analogue
IN188411B (da) *	1997-03-27	2002-09-21	Yuhan Corp
CA2410655A1 (en) *	2000-05-30	2001-12-06	John H. Dodd	Dihydropyridine compounds for the inhibition of calcium-influx
GB0130677D0 (en)	2001-12-21	2002-02-06	Glaxo Group Ltd	Medicaments and novel compounds
WO2003072597A1 (en)	2002-02-27	2003-09-04	Ferring Bv	Intermediates and methods for making heptapeptide oxytocin analogues
DE60335175D1 (de)	2002-03-28	2011-01-13	Merck Serono Sa	Thiazolidin-carbonsäureamid-derivate als modulatoren des prostaglandin-f-rezeptors
GB0208785D0 (en)	2002-04-17	2002-05-29	Medical Res Council	Treatment methtods
US7521530B2 (en)	2002-06-11	2009-04-21	Universite De Montreal	Peptides and peptidomimetics useful for inhibiting the activity of prostaglandin F2α receptor
UA78058C2 (en)	2002-07-05	2007-02-15	Applied Research Systems	Pyrrolidine derivative as oxitocin antagonists
AU2003300901A1 (en) *	2002-12-12	2004-06-30	Idenix (Cayman) Limited	Process for the production of 2'-branched nucleosides
GB0314738D0 (en)	2003-06-24	2003-07-30	Glaxo Group Ltd	Novel compounds
GB0414093D0 (en)	2004-06-23	2004-07-28	Glaxo Group Ltd	Novel compounds
JP2013509391A (ja)	2009-10-30	2013-03-14	グラクソグループリミテッド	（３ｒ，６ｒ）−３−（２，３−ジヒドロ−１ｈ−インデン−２−イル）−１−［（１ｒ）−１−（２，６−ジメチル−３−ピリジニル）−２−（４−モルホリニル）−２−オキソエチル］−６−［（１ｓ）−１−メチルプロピル］−２，５−ピペラジンジオンの新規結晶性形態
EP2845850A1 (en)	2013-09-10	2015-03-11	ObsEva S.A.	Pyrrolidine derivatives as oxytocin/vasopressin V1a receptors antagonists
EP2886107A1 (en)	2013-12-17	2015-06-24	ObsEva S.A.	Oral formulations of pyrrolydine derivatives
US20170119779A1 (en)	2014-06-16	2017-05-04	Glaxosmithkline Intellectual Property Development Limited	Retosiban for the treatment of pre-term labour
EP3753921A1 (en)	2014-07-02	2020-12-23	ObsEva S.A.	Crystalline (3z,5s)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one o-methyloxime useful in methods of treating conditions related to the ot-r activity
EP3037101B1 (en)	2014-12-22	2019-03-06	Ferring B.V.	Oxytocin receptor antagonist therapy in the luteal phase for implantation and pregnancy in women undergoing assisted reproductive technologies
CA3009576A1 (en)	2016-01-04	2017-07-13	Merck Serono S.A.	L-valinate of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof
US9447055B1 (en) *	2016-01-04	2016-09-20	Merck Serono S.A.	α-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof

2017
- 2017-01-04 CA CA3009576A patent/CA3009576A1/en active Pending
- 2017-01-04 UA UAA201806830A patent/UA125118C2/uk unknown
- 2017-01-04 SM SM20220248T patent/SMT202200248T1/it unknown
- 2017-01-04 EP EP22152238.6A patent/EP4140988A1/en active Pending
- 2017-01-04 EP EP17700392.8A patent/EP3400217B1/en active Active
- 2017-01-04 SG SG10202009723PA patent/SG10202009723PA/en unknown
- 2017-01-04 AU AU2017205254A patent/AU2017205254B2/en active Active
- 2017-01-04 PL PL17700391T patent/PL3397622T3/pl unknown
- 2017-01-04 EA EA201891095A patent/EA036990B1/ru unknown
- 2017-01-04 IL IL318222A patent/IL318222A/en unknown
- 2017-01-04 WO PCT/EP2017/050099 patent/WO2017118639A1/en not_active Ceased
- 2017-01-04 SI SI201731161T patent/SI3400217T1/sl unknown
- 2017-01-04 SG SG11201804594YA patent/SG11201804594YA/en unknown
- 2017-01-04 RS RS20220548A patent/RS63286B1/sr unknown
- 2017-01-04 MX MX2018008157A patent/MX389261B/es unknown
- 2017-01-04 HU HUE17700391A patent/HUE058872T2/hu unknown
- 2017-01-04 HU HUE17700392A patent/HUE058871T2/hu unknown
- 2017-01-04 PT PT177003910T patent/PT3397622T/pt unknown
- 2017-01-04 JP JP2018529634A patent/JP6933322B2/ja active Active
- 2017-01-04 EP EP22153566.9A patent/EP4144351A1/en active Pending
- 2017-01-04 MX MX2018008304A patent/MX379544B/es unknown
- 2017-01-04 WO PCT/EP2017/050101 patent/WO2017118641A1/en not_active Ceased
- 2017-01-04 SM SM20220249T patent/SMT202200249T1/it unknown
- 2017-01-04 JP JP2018529284A patent/JP7169573B2/ja active Active
- 2017-01-04 PL PL17700392T patent/PL3400217T3/pl unknown
- 2017-01-04 ES ES17700392T patent/ES2916835T3/es active Active
- 2017-01-04 UA UAA201806074A patent/UA125377C2/uk unknown
- 2017-01-04 HR HRP20220673TT patent/HRP20220673T1/hr unknown
- 2017-01-04 KR KR1020187018312A patent/KR20180100120A/ko not_active Ceased
- 2017-01-04 SI SI201731162T patent/SI3397622T1/sl unknown
- 2017-01-04 ES ES17700391T patent/ES2915948T3/es active Active
- 2017-01-04 DK DK17700391.0T patent/DK3397622T3/da active
- 2017-01-04 KR KR1020257022032A patent/KR20250107965A/ko active Pending
- 2017-01-04 HR HRP20220674TT patent/HRP20220674T1/hr unknown
- 2017-01-04 SG SG10202009769WA patent/SG10202009769WA/en unknown
- 2017-01-04 KR KR1020187018929A patent/KR102795275B1/ko active Active
- 2017-01-04 SG SG11201804789QA patent/SG11201804789QA/en unknown
- 2017-01-04 PT PT177003928T patent/PT3400217T/pt unknown
- 2017-01-04 AU AU2017205670A patent/AU2017205670B2/en active Active
- 2017-01-04 IL IL284912A patent/IL284912B/en unknown
- 2017-01-04 CN CN201780015011.9A patent/CN108779087A/zh active Pending
- 2017-01-04 LT LTEPPCT/EP2017/050101T patent/LT3400217T/lt unknown
- 2017-01-04 LT LTEPPCT/EP2017/050099T patent/LT3397622T/lt unknown
- 2017-01-04 MA MA043549A patent/MA43549A/fr unknown
- 2017-01-04 EP EP17700391.0A patent/EP3397622B1/en active Active
- 2017-01-04 DK DK17700392.8T patent/DK3400217T3/da active
- 2017-01-04 MA MA043580A patent/MA43580A/fr unknown
- 2017-01-04 RS RS20220547A patent/RS63285B1/sr unknown
- 2017-01-04 CA CA3009573A patent/CA3009573A1/en active Pending
2018
- 2018-05-31 IL IL259742A patent/IL259742B/en unknown
- 2018-06-26 IL IL260286A patent/IL260286B/en unknown
- 2018-06-29 MX MX2022000154A patent/MX2022000154A/es unknown
2019
- 2019-05-24 ZA ZA2019/03769A patent/ZA201903769B/en unknown
2021
- 2021-08-05 JP JP2021129297A patent/JP7432284B2/ja active Active
- 2021-08-16 AU AU2021218009A patent/AU2021218009B2/en active Active
- 2021-12-22 IL IL289256A patent/IL289256A/en unknown
2022
- 2022-06-01 CY CY20221100383T patent/CY1125223T1/el unknown
- 2022-06-01 CY CY20221100384T patent/CY1125231T1/el unknown
- 2022-10-18 JP JP2022166814A patent/JP7377588B2/ja active Active
2023
- 2023-09-21 AU AU2023233151A patent/AU2023233151A1/en not_active Abandoned
- 2023-10-25 JP JP2023183345A patent/JP2024012376A/ja active Pending
2025
- 2025-09-04 JP JP2025147215A patent/JP2026000959A/ja active Pending
- 2025-10-22 AU AU2025256134A patent/AU2025256134A1/en active Pending

Also Published As

Publication number	Publication date
CA3009576A1 (en)	2017-07-13
SMT202200248T1 (it)	2022-07-21
MX2018008157A (es)	2018-09-03
HRP20220673T1 (hr)	2022-07-08
JP7432284B2 (ja)	2024-02-16
JP7169573B2 (ja)	2022-11-11
RS63286B1 (sr)	2022-06-30
AU2021218009B2 (en)	2023-06-22
ZA201903769B (en)	2023-03-29
AU2017205254A1 (en)	2018-08-16
MX379544B (es)	2025-03-11
AU2021218009A1 (en)	2021-09-09
CN108779087A (zh)	2018-11-09
JP7377588B2 (ja)	2023-11-10
EP3400217A1 (en)	2018-11-14
EP4140988A1 (en)	2023-03-01
IL289256A (en)	2022-02-01
PL3400217T3 (pl)	2022-07-04
EA201891095A1 (ru)	2019-01-31
LT3397622T (lt)	2022-06-27
CA3009573A1 (en)	2017-07-13
JP2023002668A (ja)	2023-01-10
JP2021178858A (ja)	2021-11-18
MA43549A (fr)	2021-05-26
ES2915948T3 (es)	2022-06-27
IL318222A (en)	2025-03-01
HUE058871T2 (hu)	2022-09-28
MA43580A (fr)	2021-05-26
AU2021218003A1 (en)	2021-09-02
RS63285B1 (sr)	2022-06-30
EP3400217B1 (en)	2022-03-09
IL260286A (en)	2018-07-31
SMT202200249T1 (it)	2022-07-21
CY1125223T1 (el)	2025-03-28
JP2024012376A (ja)	2024-01-30
EP3397622B1 (en)	2022-03-09
HRP20220674T1 (hr)	2022-07-22
SI3397622T1 (sl)	2022-07-29
DK3400217T3 (da)	2022-06-07
CY1125231T1 (el)	2025-03-28
UA125118C2 (uk)	2022-01-12
KR20180100120A (ko)	2018-09-07
JP6933322B2 (ja)	2021-09-08
KR20250107965A (ko)	2025-07-14
IL259742B (en)	2021-08-31
EP3397622A1 (en)	2018-11-07
WO2017118639A1 (en)	2017-07-13
MX2022000154A (es)	2022-02-21
KR20180099708A (ko)	2018-09-05
AU2017205670A1 (en)	2018-08-16
IL260286B (en)	2022-02-01
MX2018008304A (es)	2019-01-24
WO2017118641A1 (en)	2017-07-13
EP4144351A1 (en)	2023-03-08
JP2019501897A (ja)	2019-01-24
IL284912A (en)	2021-08-31
JP2026000959A (ja)	2026-01-06
HUE058872T2 (hu)	2022-09-28
AU2017205254B2 (en)	2021-05-20
IL259742A (en)	2018-07-31
PT3400217T (pt)	2022-06-15
SI3400217T1 (sl)	2022-07-29
AU2023233151A1 (en)	2023-10-12
ES2916835T3 (es)	2022-07-06
AU2025256134A1 (en)	2025-11-13
SG11201804594YA (en)	2018-06-28
SG10202009769WA (en)	2020-11-27
KR102795275B1 (ko)	2025-04-11
SG11201804789QA (en)	2018-07-30
PL3397622T3 (pl)	2022-07-04
EA036990B1 (ru)	2021-01-25
JP2019500351A (ja)	2019-01-10
LT3400217T (lt)	2022-06-27
AU2017205670B2 (en)	2021-05-20
PT3397622T (pt)	2022-06-15
SG10202009723PA (en)	2020-11-27
IL284912B (en)	2022-07-01
UA125377C2 (uk)	2022-03-02
MX389261B (es)	2025-03-20

Publication	Publication Date	Title
DK3440128T3 (en)	2021-11-15	Recirkulation af polymermatrixkompositmateriale
DK3827838T5 (en)	2024-08-19	Hæmning af cytokin-induceret sh2-protein i nk-celler
DK3509582T3 (en)	2024-02-12	Solvatform af (r)-2-amino-3-phenylpropylcarbamat
AU201616678S (en)	2017-02-14	Cylindres
AU201614482S (en)	2016-09-05	Shakers
AU365268S (en)	2015-11-17	Pendant
AU363632S (en)	2015-08-20	Pendant
PL3222650T3 (pl)	2024-10-28	Środek dyspergujący
DK3645518T3 (en)	2021-08-02	Syntese af omecamtiv mecarbil
DK3149048T3 (en)	2020-04-14	Chloridsalt af tat-nr2b9c
DK3359556T3 (en)	2021-08-30	Modulering af gamma-c-cytokinaktivitet
AU201710564S (en)	2017-03-14	Bookrack
GB201510211D0 (en)	2015-07-29	Optical elements
GB2547884B (en)	2020-02-19	Follow focus
DK3397622T3 (en)	2022-06-07	Co-administration af alpha-aminoester af hydroxypropylthiazolidincarboxamid-derivat og et tokolytisk middel
GB2564592B (en)	2022-06-22	Laser-chain alignment
GB201500702D0 (en)	2015-03-04	Alignment aid
PL3469691T3 (pl)	2021-09-27	Konfiguracja szyku halbacha
SG11201804610RA (en)	2018-06-28	Marking-out aid
PT3554663T (pt)	2021-01-05	Sala de projecção de filmes adequada a uma projecção em grande ecrã
AU201713059S (en)	2017-05-24	SUNSHADE - square
GB201717233D0 (en)	2017-12-06	Safeguard
GB201701532D0 (en)	2017-03-15	All technologies two
AU2016376V (en)	2017-02-15	NinbellaPurple Alyogyne huegelii
GB201621467D0 (en)	2017-02-01	Modified bulgeomers